NBMI Science AB Report issue

For profit Phase 2
Founded: Solna Sweden (2011)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2015
NCT02486289
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

NBMI Science AB - subsidiary of EmeraMed Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

emeramide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mercury Poisoning (Phase 2)

Poisoning (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1